Fresenius Medical Care raises its 5008X conversion goal for 2026 to around 20% but maintains mid-single-digit operating income growth guidance.
Fresenius Medical Care (FMS) has set a new target of approximately 20% for its 5008X conversion rate in 2026, up from previous expectations. The company reaffirmed its operating income guidance, expecting mid-single-digit percentage growth for the year.
In Q2 2026, operating income growth accelerated to 23%, driven by strong performance in its FME25+ segment, which contributed EUR 67 million. Management highlighted continued profitable growth, reinforcing confidence in the company’s strategic initiatives.
The company did not disclose immediate market reactions, focusing instead on operational achievements and forward-looking targets.